Genmab — August 2017
-
Det er vi vel ikke kede af.
-
A/B har før lavet numre i lukkeauktionen..
-
Skete der noget mærkeligt i lukkeminutter?? Syntes det ser ud som om den var nede og kysse 1430 !!!!! ?
-
Ansøgning om btd får vi vel næppe noget at vide om. Os almindelige dødelige kommer vel først in the know, når btd tildeles. Hvis btd altså tildeles....
-
Men mon ikke ansøgningen er på vej med kurer. Den slags kan vi ikke betro post & telegrafen
-
Har lige opdaget dette Nordea Flash fra i formiddags "Equity Flash Comment - Flash Comment , Genmab A/S
We have been made aware that the abstract data for Tisotumab Vedotin may not be the most updated cut-off. This, despite the abstract describing that responses have increased from 6 to 7 from the abstract submission to the release of the data in the abstract. We have discussed it with Genmab and the company notes that the most updated data is from the company release on 16 June, where a 32%
-
ORR was reported, but not defined as an ORR as the study had not been finalised. This compares to the 37% mentioned in the ESMO abstract released today. We were aware that the ESMO abstract submission deadline was 10 May 2017, ie before Genmab’s headline release, but it remains somewhat confusing that the abstract describes response rates at time of release of abstract versus at time of abstract submission. In any case, the ORR of 32% (and 37% at an earlier stage described in the abstract),
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind